The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of first-line bevacizumab (BV) on the clinical outcomes of patients with metastatic colorectal cancer (mCRC) treated with second-line FOLFIRI plus BV.
Kei Muro
Honoraria - Chugai Pharma; Yakult Honsha
Research Funding - Chugai Pharma; Yakult Honsha
Takeharu Yamanaka
Honoraria - Chugai Pharma; Yakult Honsha
Mitsukuni Suenaga
No relevant relationships to disclose
Tomohiro Nishina
Honoraria - Chugai Pharma; Yakult Honsha
Hisateru Yasui
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
Takashi Ura
No relevant relationships to disclose
Tadamichi Denda
No relevant relationships to disclose
Junichi Ikeda
No relevant relationships to disclose
Taito Esaki
Honoraria - Chugai Pharma; Yakult Honsha
Research Funding - Yakult Honsha
Hogara Nishisaki
No relevant relationships to disclose
Yoshinao Takano
No relevant relationships to disclose
Ken Kondo
No relevant relationships to disclose
Koji Takeda
Honoraria - Chugai Pharma; Yakult Honsha
Yasuo Takahashi
No relevant relationships to disclose
Kazuya Endo
No relevant relationships to disclose
Yasuyuki Sugiyama
No relevant relationships to disclose